Following the news, the San Diego company's stock jumped 20% to $0.36 a share in New York.
Physicians can use the assays to evaluate the brain and spinal fluid of their patients for the presence of circulating tumor cells (CTCs) and biomarkers for patients with breast or lung cancer suspected of brain or central nervous system (CNS) metastases, the company said in a statement.
The presence of tumor cells in cerebrospinal fluid (CSF) may be an indicator of brain metastases, which occurs when cancer has spread into the CNS. Up to 30% and 36% of patients diagnosed with breast and lung cancer, respectively, will develop brain metastases.
"Testing the CSF for cancer biomarkers in patients suspected to have brain metastases can be important, as the rapid confirmation and characterization of CNS involvement enables appropriate treatment selection in a timely manner," said Dr Santosh Kesari of the Pacific Neuroscience Institute and John Wayne Cancer Institute.
"Liquid biopsy tests offer the ability to analyze an additional specimen type, beyond blood, to help physicians identify biomarkers and hence inform clinical decision making."
Biocept CEO Michael Nall said: "We are very pleased to make our Target Selector platform available for testing CSF, as a more-rapid identification of molecular alterations in brain metastases can aid physicians in choosing the best treatment options for their patients with breast or lung cancer.
“Among the significant capabilities of our technology is its versatility, which enables applications in a variety of clinical situations and for use with multiple types of biofluids."
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham